12:44 PM
 | 
Dec 07, 2017
 |  BC Extra  |  Clinical News

Cancer Research Institute publishes analysis of immuno-oncology field

Cancer Research Institute performed a deep dive of immuno-oncology development and found that while there are a number of promising therapies, the field is inefficient and filled with duplicate and uncoordinated trials. In a report published in Annals of Oncology, researchers from the Anna-Maria Kellen Clinical Accelerator at CRI propose solutions for enhancing efficiencies across the immuno-oncology landscape, including new trial designs and third-party coordination of clinical trials.

As of September 2017, the researchers identified 940 immunotherapies in clinical development and another 1,064 in preclinical research, with 3,042 active clinical trials evaluating the agents. However, almost half of the 940 immunotherapies target only 40 targets, highlighting extensive duplication.

The researchers closely examined...

Read the full 544 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >